Clinical Trial Update: Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy [Phase 2]

View source ↗

Summary

This document announces the completion of a Phase 2 study of VX-765 in adults with treatment-resistant partial epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy

Drugs mentioned

• VX-765 (belnacasan)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Partial Epilepsy | Phase 2 | Status: COMPLETED